Clinical Characteristics and Outcomes of Patients With Diabetes and COVID-19 in Association With Glucose-Lowering Medication
Chen et al.
, Clinical Characteristics and Outcomes of Patients With Diabetes and COVID-19 in Association With..
, Diabetes Care, doi:10.2337/dc20-0660
Retrospective 120 COVID-19 diabetes patients, showing non-statistically significantly lower mortality with existing metformin treatment.
Although the 33% lower mortality is not statistically significant, it is consistent with the significant 32% lower mortality [27‑37%]
from meta analysis of the 46 mortality results to date
risk of death, 33.0% lower, RR 0.67, p = 0.46, treatment 4 of 43 (9.3%), control 15 of 77 (19.5%), NNT 9.8, adjusted per study, odds ratio converted to relative risk.
Effect extraction follows pre-specified rules prioritizing more serious outcomes. Submit updates
Chen et al., 31 Jul 2020, retrospective, China, peer-reviewed, 12 authors.
Abstract: Diabetes Care Volume 43, July 2020
Yuchen Chen,1 Dong Yang,1 Biao Cheng,2
Jian Chen,2 Anlin Peng,3 Chen Yang,1
Chong Liu,4 Mingrui Xiong,1 Aiping Deng,2
Yu Zhang,1 Ling Zheng,4 and Kun Huang1
Diabetes Care 2020;43:1399–1407 | https://doi.org/10.2337/dc20-0660
Diabetes is one of the most distinct comorbidities of COVID-19. Here, we describe
the clinical characteristics of and outcomes in patients with diabetes in whom
COVID-19 was conﬁrmed or clinically diagnosed (with typical features on lung
imaging and symptoms) and their association with glucose-lowering or blood
RESEARCH DESIGN AND METHODS
In this retrospective study involving 904 patients with COVID-19 (136 with diabetes,
mostly type 2 diabetes), clinical and laboratory characteristics were collected and
compared between the group with diabetes and the group without diabetes, and
between groups taking different medications. Logistic regression was used to
explore risk factors associated with mortality or poor prognosis.
The proportion of comorbid diabetes is similar between cases of conﬁrmed and of
clinically diagnosed COVID-19. Risk factors for higher mortality of patients with
diabetes and COVID-19 were older age (adjusted odds ratio [aOR] 1.09 [95% CI 1.04,
1.15] per year increase; P 5 0.001) and elevated C-reactive protein (aOR 1.12 [95% CI
1.00, 1.24]; P 5 0.043). Insulin usage (aOR 3.58 [95% CI 1.37, 9.35]; P 5 0.009) was
associated with poor prognosis. Clinical outcomes of those who use an ACE inhibitor
(ACEI) or angiotensin II type-I receptor blocker (ARB) were comparable with those of
patients who do not use ACEI/ARB among COVID-19 patients with diabetes and
Tongji School of Pharmacy, Tongji Medical
College, Huazhong University of Science and
Technology, Wuhan, China
Department of Pharmacy and the Center of
Information, The Central Hospital of Wuhan,
Tongji Medical College, Huazhong University
of Science and Technology, Wuhan, China
Department of Pharmacy, The Third Hospital of
Wuhan, Wuhan, China
Hubei Key Laboratory of Cell Homeostasis, College of Life Sciences, Wuhan University, Wuhan,
Corresponding authors: Kun Huang, kunhuang@
hust.edu.cn, and Ling Zheng, email@example.com
Received 28 March 2020 and accepted 24 April
This article contains supplementary material online
Y.C., D.Y., and B.C. contributed equally.
This article is part of a special article collection
available at https://care.diabetesjournals.org/
C-reactive protein may help to identify patients with diabetes who are at greater risk
of dying during hospitalization. Older patients with diabetes were prone to death
related to COVID-19. Attention needs to be paid to patients with diabetes and
COVID-19 who use insulin. ACEI/ARB use showed no signiﬁcant impact on
patients with diabetes and hypertension who have COVID-19.
© 2020 by the American Diabetes Association.
Readers may use this article as long as the work is
properly cited, the use is educational and not for
proﬁt, and the work is not altered. More information is available at https://www.diabetesjournals
DIABETES AND COVID-19
Clinical Characteristics and
Outcomes of Patients With
Diabetes and COVID-19 in
Association With GlucoseLowering Medication
Features of Patients With Diabetes and COVID-19
Coronavirus disease 2019 (COVID-19)..
Please send us corrections, updates, or comments. Vaccines and
treatments are complementary. All practical, effective, and safe means should
be used based on risk/benefit analysis. No treatment, vaccine, or intervention
is 100% available and effective for all current and future variants. We do not
provide medical advice. Before taking any medication, consult a qualified
physician who can provide personalized advice and details of risks and
benefits based on your medical history and situation. FLCCC
provide treatment protocols.